Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2009 Oct;31(10):745-9.
doi: 10.1097/MPH.0b013e3181b794d0.

Evaluation of the effects of different transfusion trigger levels during the treatment of childhood acute lymphoblastic leukemia

Affiliations
Comparative Study

Evaluation of the effects of different transfusion trigger levels during the treatment of childhood acute lymphoblastic leukemia

Pauliina Paananen et al. J Pediatr Hematol Oncol. 2009 Oct.

Abstract

Differences in the triggering levels for red blood cell (RBC) and platelet (PLT) transfusions were analyzed in association to the amount and total costs of transfusions and the number of febrile episodes during childhood acute lymphoblastic leukemia (ALL) treatment. Transfusions are given with hemoglobin (Hb) < or =90 to 100 g/L and PLT count < or =20 to 30 x 10(9)/L in Tampere, and with Hb < or =80 g/L and PLT count < or =10 x 10(9)/L in Turku. Median pretransfusion PLT count was 48 x 10(9)/L in Tampere, and 16 x 10(9)/L in Turku. The number and costs of PLT transfusions were 35% higher in Tampere. Median Hb before transfusion was 95 g/L in Tampere, and 77 g/L in Turku. The costs of RBC transfusions were 29% lower in Turku as child units (90 mL) were preferred. The number of RBC transfusions was associated with the treatment protocol (P=0.001), and PLT transfusions with the treatment protocol (P<0.001) and the treatment center (P=0.04). The number of febrile episodes was associated with the treatment protocol (P=0.03), and age at diagnosis (P=0.07). Lower trigger levels did not cause more delays or complications in treatment. Clinical trials are, however, necessary to determine optimal criteria for supportive blood transfusions in childhood cancer patients.

PubMed Disclaimer

Publication types

LinkOut - more resources